Collaboration and License Agreements - Ono Collaboration and Option Agreement (Details) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 04, 2020	Sep. 14, 2018	Oct. 31, 2018	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 28, 2022	Dec. 31, 2021
Collaboration agreement
Collaboration contract asset				$ 9,108,000		$ 9,108,000			$ 9,870,000
Revenue recognized				18,549,000	$ 13,412,000	$ 36,963,000	$ 24,552,000
Expected Ressarch Services Period						4 years
Ono Pharmaceutical Co. Ltd
Collaboration agreement
Milestone payments		$ 10,000,000.0
Non-refundable upfront payments recorded as deferred revenue	$ 10,000,000.0	10,000,000.0
Aggregate research and development fees payments receivable	20,000,000.0	29,300,000
Collaborative arrangement annual payments receivable recorded as deferred revenue			$ 5,000,000.0
Collaborative arrangement potential additional milestones		20,000,000.0
First-year research and development fees prepayment			$ 5,000,000.0
Transaction price of the agreement		$ 39,300,000
Sublicense consideration paid				4,000,000.0		$ 4,000,000.0
Collaboration contract asset				4,000,000.0		4,000,000.0
Amortization of sublicense consideration				0	300,000	300,000	500,000
Revenue recognized				400,000		2,900,000
Research and development fees cash payments received						18,000,000.0
Ono Pharmaceutical Co. Ltd | Candidate 2
Collaboration agreement
Percentage of reduction on milestone payments		50.00%
Ono Pharmaceutical Co. Ltd | Minimum | Candidate 1
Collaboration agreement
Collaborative arrangement potential additional milestones								$ 9,300,000
Ono Pharmaceutical Co. Ltd | Maximum | Candidate 1
Collaboration agreement
Collaborative arrangement potential additional milestones								$ 29,300,000
Ono Pharmaceutical Co. Ltd | Maximum | Candidate 2
Collaboration agreement
Aggregate milestone payments		$ 843,000,000.0
Ono Pharmaceutical Co. Ltd | Collaborative Arrangement
Collaboration agreement
Revenue recognized					2,500,000		5,000,000.0
Ono Pharmaceutical Co. Ltd | Collaborative Arrangement | Research services
Collaboration agreement
Revenue recognized					1,300,000		2,500,000
Ono Pharmaceutical Co. Ltd | Collaborative Arrangement | Upfront Fee
Collaboration agreement
Revenue recognized				200,000	$ 1,200,000	1,500,000	$ 2,500,000
Ono Pharmaceutical Co. Ltd | Collaborative Arrangement | Minimum
Collaboration agreement
Profits and losses sharing percentage		50.00%
Ono Letter Agreement | Ono Pharmaceutical Co. Ltd
Collaboration agreement
Milestone payments	$ 10,000,000.0
Milestone payments recorded to deferred revenue		$ 10,000,000.0
Revenue recognized				$ 200,000		$ 1,400,000